{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T12:32:00Z","timestamp":1793968320174,"version":"4.8.0"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T00:00:00Z","timestamp":1673568000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T00:00:00Z","timestamp":1673568000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Hallym University Research Fund"},{"name":"Basic Science Research Program through the National Research Foundation of Korea, funded by the Ministry of Education, Science and Technology","award":["NRF-2018M3A9F3020956"],"award-info":[{"award-number":["NRF-2018M3A9F3020956"]}]},{"name":"Basic Science Research Program through the National Research Foundation of Korea, funded by the Ministry of Education, Science and Technology","award":["NRF-2019R1I1A3A01060447"],"award-info":[{"award-number":["NRF-2019R1I1A3A01060447"]}]},{"name":"Basic Science Research Program through the National Research Foundation of Korea, funded by the Ministry of Education, Science and Technology","award":["NRF-2020R1I1A3073530"],"award-info":[{"award-number":["NRF-2020R1I1A3073530"]}]},{"name":"Basic Science Research Program through the National Research Foundation of Korea, funded by the Ministry of Education, Science and Technology","award":["NRF-2020R1A6A1A03043026"],"award-info":[{"award-number":["NRF-2020R1A6A1A03043026"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The metabolites of gut microbiota show favorable therapeutic effects on nonalcoholic fatty liver disease (NAFLD), but the active metabolites and mechanisms against NAFLD have not been documented. The aim of the study was to investigate the active metabolites and mechanisms of gut microbiota against NAFLD by network pharmacology. We obtained a total of 208 metabolites from the gutMgene database and retrieved 1256 targets from similarity ensemble approach (SEA) and 947 targets from the SwissTargetPrediction (STP) database. In the SEA and STP databases, we identified 668 overlapping targets and obtained 237 targets for NAFLD. Thirty-eight targets were identified out of those 237 and 223 targets retrieved from the gutMgene database, and were considered the final NAFLD targets of metabolites from the microbiome. The results of molecular docking tests suggest that, of the 38 targets, mitogen-activated protein kinase 8-compound K and glycogen synthase kinase-3 beta-myricetin complexes might inhibit the Wnt signaling pathway. The microbiota-signaling pathways-targets-metabolites network analysis reveals that\n                    <jats:italic>Firmicutes, Fusobacteria<\/jats:italic>\n                    , the Toll-like receptor signaling pathway, mitogen-activated protein kinase 1, and phenylacetylglutamine are notable components of NAFLD and therefore to understanding its processes and possible therapeutic approaches. The key components and potential mechanisms of metabolites from gut microbiota against NAFLD were explored utilizing network pharmacology analyses. This study provides scientific evidence to support the therapeutic efficacy of metabolites for NAFLD and suggests holistic insights on which to base further research.\n                  <\/jats:p>","DOI":"10.1038\/s41598-023-27885-w","type":"journal-article","created":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T09:03:55Z","timestamp":1673600635000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["The identification of metabolites from gut microbiota in NAFLD via network pharmacology"],"prefix":"10.1038","volume":"13","author":[{"given":"Ki-Kwang","family":"Oh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haripriya","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byeong Hyun","family":"Min","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raja","family":"Ganesan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satya Priya","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Min","family":"Won","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Ju","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su Been","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min Gi","family":"Cha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Goo Hyun","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min Kyo","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Ye","family":"Hyun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung A","family":"Eom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hee Jin","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Jun","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mi Ran","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong Joon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ki Tae","family":"Suk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,13]]},"reference":[{"key":"27885_CR1","first-page":"36","volume":"361","author":"AM Valdes","year":"2018","unstructured":"Valdes, A. M., Walter, J., Segal, E. & Spector, T. D. Role of the gut microbiota in nutrition and health. BMJ 361, 36\u201344 (2018).","journal-title":"BMJ"},{"key":"27885_CR2","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.3389\/fmicb.2020.572921","volume":"11","author":"SK Dogra","year":"2020","unstructured":"Dogra, S. K., Dor\u00e9, J. & Damak, S. Gut microbiota resilience: Definition, link to health and strategies for intervention. Front. Microbiol. 11, 2245 (2020).","journal-title":"Front. Microbiol."},{"key":"27885_CR3","doi-asserted-by":"publisher","first-page":"F1211","DOI":"10.1152\/ajprenal.00298.2018","volume":"316","author":"GP Hobby","year":"2019","unstructured":"Hobby, G. P. et al. Chronic kidney disease and the gut microbiome. Am. J. Physiol. Renal Physiol. 316, F1211\u2013F1217 (2019).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"27885_CR4","doi-asserted-by":"publisher","first-page":"7657","DOI":"10.1007\/s00253-020-10771-0","volume":"104","author":"NS Dosoky","year":"2020","unstructured":"Dosoky, N. S., May-Zhang, L. S. & Davies, S. S. Engineering the gut microbiota to treat chronic diseases. Appl. Microbiol. Biotechnol. 104, 7657\u20137671 (2020).","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"27885_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/nu12082189","volume":"12","author":"J \u017b\u00f3\u0142kiewicz","year":"2020","unstructured":"\u017b\u00f3\u0142kiewicz, J., Marzec, A., Ruszczy\u0144ski, M. & Feleszko, W. Postbiotics\u2014A step beyond pre- and probiotics. Nutrients 12, 1\u201317 (2020).","journal-title":"Nutrients"},{"key":"27885_CR6","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1002\/cld.1010","volume":"17","author":"SAM Albhaisi","year":"2021","unstructured":"Albhaisi, S. A. M. & Bajaj, J. S. The influence of the microbiome on NAFLD and NASH. Clin. Liver Dis. 17, 15\u201318. https:\/\/doi.org\/10.1002\/cld.1010 (2021).","journal-title":"Clin. Liver Dis."},{"key":"27885_CR7","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1111\/lam.13333","volume":"72","author":"S Ahlawat","year":"2021","unstructured":"Ahlawat, S. & Sharma, K. K. Gut\u2013organ axis: a microbial outreach and networking. Lett. Appl. Microbiol. 72, 636\u2013668. https:\/\/doi.org\/10.1111\/lam.13333 (2021).","journal-title":"Lett. Appl. Microbiol."},{"key":"27885_CR8","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.jhepr.2019.04.004","volume":"1","author":"KJ Schwenger","year":"2019","unstructured":"Schwenger, K. J., Clermont-Dejean, N. & Allard, J. P. The role of the gut microbiome in chronic liver disease: The clinical evidence revised. JHEP Rep. 1, 214\u2013226 (2019).","journal-title":"JHEP Rep."},{"key":"27885_CR9","first-page":"1","volume":"21","author":"J Chen","year":"2020","unstructured":"Chen, J. & Vitetta, L. Gut microbiota metabolites in NAFLD pathogenesis and therapeutic implications. Int. J. Mol. Sci. 21, 1\u201319 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"27885_CR10","first-page":"86","volume":"11","author":"Y Chen","year":"2021","unstructured":"Chen, Y., Zhou, J. & Wang, L. Role and mechanism of gut microbiota in human disease. Front. Cell. Infect. Microbiol. 11, 86 (2021).","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"27885_CR11","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/s41422-020-0332-7","volume":"30","author":"D Zheng","year":"2020","unstructured":"Zheng, D., Liwinski, T. & Elinav, E. Interaction between microbiota and immunity in health and disease. Cell Res. 30, 492\u2013506 (2020).","journal-title":"Cell Res."},{"key":"27885_CR12","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1016\/j.jhep.2017.05.007","volume":"67","author":"R Wiest","year":"2017","unstructured":"Wiest, R., Albillos, A., Trauner, M., Bajaj, J. S. & Jalan, R. Targeting the gut-liver axis in liver disease. J. Hepatol. 67, 1084\u20131103 (2017).","journal-title":"J. Hepatol."},{"key":"27885_CR13","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1002\/hep4.1331","volume":"3","author":"N Ohtani","year":"2019","unstructured":"Ohtani, N. & Kawada, N. Role of the gut\u2013liver axis in liver inflammation, fibrosis, and cancer: A special focus on the gut microbiota relationship. Hepatol. Commun 3, 456 (2019).","journal-title":"Hepatol. Commun"},{"key":"27885_CR14","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1136\/gutjnl-2018-316307","volume":"68","author":"H Chu","year":"2019","unstructured":"Chu, H., Duan, Y., Yang, L. & Schnabl, B. Small metabolites, possible big changes: A microbiota-centered view of non-alcoholic fatty liver disease. Gut 68, 359\u2013370 (2019).","journal-title":"Gut"},{"key":"27885_CR15","doi-asserted-by":"publisher","first-page":"300","DOI":"10.3390\/ijms17030300","volume":"17","author":"X He","year":"2016","unstructured":"He, X., Ji, G., Jia, W. & Li, H. Gut microbiota and nonalcoholic fatty liver disease: Insights on mechanism and application of metabolomics. Int. J. Mol. Sci. 17, 300 (2016).","journal-title":"Int. J. Mol. Sci."},{"key":"27885_CR16","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1111\/apt.15314","volume":"50","author":"S Jayakumar","year":"2019","unstructured":"Jayakumar, S. & Loomba, R. Review article: emerging role of the gut microbiome in the progression of nonalcoholic fatty liver disease and potential therapeutic implications. Aliment. Pharmacol. Ther. 50, 144 (2019).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"27885_CR17","first-page":"1935","volume":"18","author":"Q Liu","year":"2019","unstructured":"Liu, Q. et al. Role and effective therapeutic target of gut microbiota in NAFLD\/NASH. Exp. Ther. Med. 18, 1935 (2019).","journal-title":"Exp. Ther. Med."},{"key":"27885_CR18","first-page":"11","volume":"7","author":"J Zhou","year":"2021","unstructured":"Zhou, J., Tripathi, M., Sinha, R. A., Singh, B. K. & Yen, P. M. Gut microbiota and their metabolites in the progression of non-alcoholic fatty liver disease. Hepatoma Res. 7, 11 (2021).","journal-title":"Hepatoma Res."},{"key":"27885_CR19","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.3390\/nu14081533","volume":"14","author":"M Muc-Wierzgon","year":"2022","unstructured":"Muc-Wierzgon, M. et al. Network pharmacology exploration reveals gut microbiota modulation as a common therapeutic mechanism for anti-fatigue effect treated with maca compounds prescription. Nutrients 14, 1533 (2022).","journal-title":"Nutrients"},{"key":"27885_CR20","doi-asserted-by":"publisher","first-page":"22","DOI":"10.3350\/cmh.2020.0129","volume":"27","author":"E Jennison","year":"2020","unstructured":"Jennison, E. & Byrne, C. D. The role of the gut microbiome and diet in the pathogenesis of non-alcoholic fatty liver disease. Clin. Mol. Hepatol. 27, 22\u201343 (2020).","journal-title":"Clin. Mol. Hepatol."},{"key":"27885_CR21","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/nbt1284","volume":"25","author":"MJ Keiser","year":"2007","unstructured":"Keiser, M. J. et al. Relating protein pharmacology by ligand chemistry. Nat. Biotechnol. 25, 197\u2013206 (2007).","journal-title":"Nat. Biotechnol."},{"key":"27885_CR22","doi-asserted-by":"publisher","first-page":"W357","DOI":"10.1093\/nar\/gkz382","volume":"47","author":"A Daina","year":"2019","unstructured":"Daina, A., Michielin, O. & Zoete, V. SwissTargetPrediction: Updated data and new features for efficient prediction of protein targets of small molecules. Nucleic Acids Res. 47, W357\u2013W364 (2019).","journal-title":"Nucleic Acids Res."},{"key":"27885_CR23","first-page":"D845","volume":"48","author":"J Pi\u00f1ero","year":"2020","unstructured":"Pi\u00f1ero, J. et al. The DisGeNET knowledge platform for disease genomics: 2019 update. Nucleic Acids Res. 48, D845\u2013D855 (2020).","journal-title":"Nucleic Acids Res."},{"key":"27885_CR24","doi-asserted-by":"publisher","first-page":"D514","DOI":"10.1093\/nar\/gki033","volume":"33","author":"A Hamosh","year":"2005","unstructured":"Hamosh, A., Scott, A. F., Amberger, J. S., Bocchini, C. A. & McKusick, V. A. Online Mendelian Inheritance in Man (OMIM), a knowledgebase of human genes and genetic disorders. Nucleic Acids Res. 33, D514 (2005).","journal-title":"Nucleic Acids Res."},{"key":"27885_CR25","doi-asserted-by":"publisher","first-page":"e3751","DOI":"10.7717\/peerj.3751","volume":"2017","author":"L Shi","year":"2017","unstructured":"Shi, L. et al. Gene expression profiling and functional analysis reveals that p53 pathway-related gene expression is highly activated in cancer cells treated by cold atmospheric plasma-activated medium. PeerJ 2017, e3751 (2017).","journal-title":"PeerJ"},{"key":"27885_CR26","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s13659-020-00260-2","volume":"10","author":"P Khanal","year":"2020","unstructured":"Khanal, P., Patil, B. M., Chand, J. & Naaz, Y. Anthraquinone derivatives as an immune booster and their therapeutic option against COVID-19. Nat. Prod. Bioprospect. 10, 325 (2020).","journal-title":"Nat. Prod. Bioprospect."},{"key":"27885_CR27","doi-asserted-by":"publisher","first-page":"2778","DOI":"10.1021\/ci200227u","volume":"51","author":"RA Laskowski","year":"2011","unstructured":"Laskowski, R. A. & Swindells, M. B. LigPlot+: Multiple ligand-protein interaction diagrams for drug discovery. J. Chem. Inf. Model. 51, 2778\u20132786. https:\/\/doi.org\/10.1021\/ci200227u (2011).","journal-title":"J. Chem. Inf. Model."},{"key":"27885_CR28","first-page":"23","volume":"7","author":"S Shityakov","year":"2014","unstructured":"Shityakov, S. & F\u00f6rster, C. In silico predictive model to determine vector-mediated transport properties for the blood\u2013brain barrier choline transporter. Adv. Appl. Bioinform. Chem. 7, 23\u201336 (2014).","journal-title":"Adv. Appl. Bioinform. Chem."},{"key":"27885_CR29","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1002\/cmdc.201600182","volume":"11","author":"A Daina","year":"2016","unstructured":"Daina, A. & Zoete, V. A BOILED-egg to predict gastrointestinal absorption and brain penetration of small molecules. ChemMedChem 11, 1117\u20131121. https:\/\/doi.org\/10.1002\/cmdc.201600182 (2016).","journal-title":"ChemMedChem"},{"key":"27885_CR30","doi-asserted-by":"publisher","first-page":"20387","DOI":"10.1074\/jbc.M116.743138","volume":"291","author":"SM Lamothe","year":"2016","unstructured":"Lamothe, S. M., Guo, J., Li, W., Yang, T. & Zhang, S. The human ether-a-go-go-related gene (hERG) potassium channel represents an unusual target for protease-mediated damage. J. Biol. Chem. 291, 20387 (2016).","journal-title":"J. Biol. Chem."},{"key":"27885_CR31","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1021\/acs.chemrestox.5b00465","volume":"29","author":"D Mulliner","year":"2016","unstructured":"Mulliner, D. et al. Computational models for human and animal hepatotoxicity with a global application scope. Chem. Res. Toxicol. 29, 757\u2013767. https:\/\/doi.org\/10.1021\/acs.chemrestox.5b00465 (2016).","journal-title":"Chem. Res. Toxicol."},{"key":"27885_CR32","doi-asserted-by":"publisher","first-page":"2840","DOI":"10.1021\/ci300400a","volume":"52","author":"C Xu","year":"2012","unstructured":"Xu, C. et al. In silico prediction of chemical ames mutagenicity. J. Chem. Inf. Model. 52, 2840\u20132847. https:\/\/doi.org\/10.1021\/ci300400a (2012).","journal-title":"J. Chem. Inf. Model."},{"key":"27885_CR33","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.taap.2014.12.014","volume":"284","author":"VM Alves","year":"2015","unstructured":"Alves, V. M. et al. Predicting chemically-induced skin reactions. Part I: QSAR models of skin sensitization and their application to identify potentially hazardous compounds. Toxicol. Appl. Pharmacol. 284, 262 (2015).","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"27885_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13321-016-0117-7","volume":"8","author":"T Lei","year":"2016","unstructured":"Lei, T. et al. ADMET evaluation in drug discovery: 15 Accurate prediction of rat oral acute toxicity using relevance vector machine and consensus modeling. J. Cheminform. 8, 1\u201319. https:\/\/doi.org\/10.1186\/s13321-016-0117-7 (2016).","journal-title":"J. Cheminform."},{"key":"27885_CR35","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1021\/acs.jcim.5b00238","volume":"55","author":"Y Xu","year":"2015","unstructured":"Xu, Y. et al. Deep learning for drug-induced liver injury. J. Chem. Inf. Model. 55, 2085\u20132093. https:\/\/doi.org\/10.1021\/acs.jcim.5b00238 (2015).","journal-title":"J. Chem. Inf. Model."},{"key":"27885_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13321-018-0283-x","volume":"10","author":"J Dong","year":"2018","unstructured":"Dong, J. et al. Admetlab: A platform for systematic ADMET evaluation based on a comprehensively collected ADMET database. J. Cheminform. 10, 1\u201311. https:\/\/doi.org\/10.1186\/s13321-018-0283-x (2018).","journal-title":"J. Cheminform."},{"key":"27885_CR37","doi-asserted-by":"publisher","first-page":"D587","DOI":"10.1093\/nar\/gkac963","volume":"51","author":"M Kanehisa","year":"2022","unstructured":"Kanehisa, M., Furumichi, M., Sato, Y., Kawashima, M. & Ishiguro-Watanabe, M. KEGG for taxonomy-based analysis of pathways and genomes. Nucleic Acids Res. 51, D587\u2013D589 (2022).","journal-title":"Nucleic Acids Res."},{"key":"27885_CR38","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1038\/s43018-020-00167-4","volume":"2","author":"Y Gocho","year":"2021","unstructured":"Gocho, Y. et al. Network-based systems pharmacology reveals heterogeneity in LCK and BCL2 signaling and therapeutic sensitivity of T-cell acute lymphoblastic leukemia. Nat. Cancer 2, 284\u2013299 (2021).","journal-title":"Nat. Cancer"},{"key":"27885_CR39","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1172\/JCI95802","volume":"128","author":"SH Jeong","year":"2018","unstructured":"Jeong, S. H. et al. Hippo-mediated suppression of IRS2\/AKT signaling prevents hepatic steatosis and liver cancer. J. Clin. Investig. 128, 1010\u20131025 (2018).","journal-title":"J. Clin. Investig."},{"key":"27885_CR40","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1111\/j.1572-0241.2007.01774.x","volume":"103","author":"A Wieckowska","year":"2008","unstructured":"Wieckowska, A. et al. Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis. Am. J. Gastroenterol. 103, 1372\u20131379 (2008).","journal-title":"Am. J. Gastroenterol."},{"key":"27885_CR41","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1074\/jbc.M210062200","volume":"278","author":"S Yu","year":"2003","unstructured":"Yu, S. et al. Adipocyte-specific gene expression and adipogenic steatosis in the mouse liver due to peroxisome proliferator-activated receptor \u03b31 (PPAR\u03b31) overexpression. J. Biol. Chem. 278, 498\u2013505 (2003).","journal-title":"J. Biol. Chem."},{"key":"27885_CR42","doi-asserted-by":"publisher","first-page":"100584","DOI":"10.1016\/j.aohep.2021.100584","volume":"27","author":"SS Jin","year":"2022","unstructured":"Jin, S. S., Lin, C. J., Lin, X. F., Zheng, J. Z. & Guan, H. Q. Silencing lncRNA NEAT1 reduces nonalcoholic fatty liver fat deposition by regulating the miR-139\u20135p\/c-Jun\/SREBP-1c pathway. Ann. Hepatol. 27, 100584 (2022).","journal-title":"Ann. Hepatol."},{"key":"27885_CR43","doi-asserted-by":"publisher","first-page":"e0210828","DOI":"10.1371\/journal.pone.0210828","volume":"14","author":"S Choung","year":"2019","unstructured":"Choung, S. et al. Epidermal growth factor receptor inhibition attenuates non-alcoholic fatty liver disease in diet-induced obese mice. PLoS ONE 14, e0210828 (2019).","journal-title":"PLoS ONE"},{"key":"27885_CR44","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1002\/hep.26746","volume":"59","author":"ITW Harley","year":"2014","unstructured":"Harley, I. T. W. et al. IL-17 signaling accelerates the progression of nonalcoholic fatty liver disease in mice. Hepatology 59, 1830 (2014).","journal-title":"Hepatology"},{"key":"27885_CR45","doi-asserted-by":"publisher","first-page":"685","DOI":"10.3892\/mmr.2019.10872\/abstract","volume":"21","author":"J Wang","year":"2020","unstructured":"Wang, J., Liu, H., Xie, G., Cai, W. & Xu, J. Identification of hub genes and key pathways of dietary advanced glycation end products-induced non-alcoholic fatty liver disease by bioinformatics analysis and animal experiments. Mol. Med. Rep. 21, 685\u2013694. https:\/\/doi.org\/10.3892\/mmr.2019.10872\/abstract (2020).","journal-title":"Mol. Med. Rep."},{"key":"27885_CR46","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.3389\/fimmu.2020.01352","volume":"11","author":"R Schierwagen","year":"2020","unstructured":"Schierwagen, R. et al. The role of macrophage-inducible C-type lectin in different stages of chronic liver disease. Front. Immunol. 11, 1352 (2020).","journal-title":"Front. Immunol."},{"key":"27885_CR47","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1002\/hep4.1158","volume":"2","author":"Y Osawa","year":"2018","unstructured":"Osawa, Y. et al. Tumor necrosis factor-\u03b1-mediated hepatocyte apoptosis stimulates fibrosis in the steatotic liver in mice. Hepatology Communications. 2, 407\u2013420. https:\/\/doi.org\/10.1002\/hep4.1158 (2018).","journal-title":"Hepatology Communications."},{"key":"27885_CR48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-016-0001-8","volume":"6","author":"S Kim","year":"2016","unstructured":"Kim, S., Park, S., Kim, B. & Kwon, J. Toll-like receptor 7 affects the pathogenesis of non-alcoholic fatty liver disease. Sci. Rep. 6, 1\u201315 (2016).","journal-title":"Sci. Rep."},{"key":"27885_CR49","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.3389\/fendo.2021.760860","volume":"12","author":"P Hirsova","year":"2021","unstructured":"Hirsova, P., Bamidele, A. O., Wang, H., Povero, D. & Revelo, X. S. Emerging roles of T cells in the pathogenesis of nonalcoholic steatohepatitis and hepatocellular carcinoma. Front. Endocrinol. 12, 1432 (2021).","journal-title":"Front. Endocrinol."},{"key":"27885_CR50","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1097\/MCG.0000000000000784","volume":"52","author":"K Wijarnpreecha","year":"2018","unstructured":"Wijarnpreecha, K. et al. Helicobacter pylori and risk of nonalcoholic fatty liver disease: A systematic review and meta-analysis. J. Clin. Gastroenterol. 52, 386\u2013391 (2018).","journal-title":"J. Clin. Gastroenterol."},{"key":"27885_CR51","first-page":"1","volume":"10","author":"T Xu","year":"2018","unstructured":"Xu, T. et al. New insights into Nod-like receptors (NLRs) in liver diseases. Int. J. Physiol. Pathophysiol. Pharmacol. 10, 1 (2018).","journal-title":"Int. J. Physiol. Pathophysiol. Pharmacol."},{"key":"27885_CR52","first-page":"1","volume":"12","author":"YD Wang","year":"2021","unstructured":"Wang, Y. D. et al. New insight of obesity-associated NAFLD: Dysregulated \u201ccrosstalk\u201d between multi-organ and the liver? Genes Dis. 12, 1\u201314 (2021).","journal-title":"Genes Dis."},{"key":"27885_CR53","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1016\/j.jhep.2018.01.035","volume":"68","author":"P Zhang","year":"2018","unstructured":"Zhang, P. et al. Prolactin improves hepatic steatosis via CD36 pathway. J. Hepatol. 68, 1247\u20131255 (2018).","journal-title":"J. Hepatol."},{"key":"27885_CR54","doi-asserted-by":"publisher","first-page":"3436","DOI":"10.1096\/fj.15-271171","volume":"29","author":"S Wang","year":"2015","unstructured":"Wang, S. et al. Nonalcoholic fatty liver disease induced by noncanonical Wnt and its rescue by Wnt3a. FASEB J. 29, 3436\u20133445 (2015).","journal-title":"FASEB J."},{"key":"27885_CR55","doi-asserted-by":"publisher","first-page":"e62409","DOI":"10.1371\/journal.pone.0062409","volume":"8","author":"KA Kim","year":"2013","unstructured":"Kim, K. A., Jung, I. H., Park, S. H., Ahn, Y. T., Huh, C. S. & Kim, D. H. Comparative analysis of the gut microbiota in people with different levels of ginsenoside Rb1 degradation to compound K. PLoS ONE 8, e62409 (2013).","journal-title":"PLoS ONE"},{"key":"27885_CR56","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1517\/17425255.2014.918954","volume":"10","author":"LY Du","year":"2014","unstructured":"Du, L. Y. et al. Identification of the metabolites of myricitrin produced by human intestinal bacteria in vitro using ultra-performance liquid chromatography\/quadrupole time-of-flight mass spectrometry. Expert Opin. Drug Metab. Toxicol, 10, 921\u2013931 (2014).","journal-title":"Expert Opin. Drug Metab. Toxicol,"},{"key":"27885_CR57","doi-asserted-by":"publisher","DOI":"10.1128\/mSystems.00122-19","author":"AC Wong","year":"2019","unstructured":"Wong, A. C. & Levy, M. New approaches to microbiome-based therapies. mSystems. https:\/\/doi.org\/10.1128\/mSystems.00122-19 (2019).","journal-title":"mSystems."},{"key":"27885_CR58","doi-asserted-by":"publisher","first-page":"81","DOI":"10.12938\/bmfh.18-032","volume":"38","author":"COM Jasirwan","year":"2019","unstructured":"Jasirwan, C. O. M., Lesmana, C. R. A., Hasan, I., Sulaiman, A. S. & Gani, R. A. The role of gut microbiota in non-alcoholic fatty liver disease: Pathways of mechanisms. Biosci. Microbiota Food Health. 38, 81 (2019).","journal-title":"Biosci. Microbiota Food Health."},{"key":"27885_CR59","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/j.aohep.2019.06.020","volume":"18","author":"QZ Guohong-Liu","year":"2019","unstructured":"Guohong-Liu, Q. Z. Characteristics of intestinal bacteria with fatty liver diseases and cirrhosis. Ann. Hepatol. 18, 796\u2013803 (2019).","journal-title":"Ann. Hepatol."},{"key":"27885_CR60","doi-asserted-by":"publisher","first-page":"494","DOI":"10.3390\/nu13020494","volume":"13","author":"L Abenavoli","year":"2021","unstructured":"Abenavoli, L. et al. Dietary polyphenols and non-alcoholic fatty liver disease. Nutrients 13, 494 (2021).","journal-title":"Nutrients"},{"key":"27885_CR61","doi-asserted-by":"publisher","first-page":"101190","DOI":"10.1016\/j.molmet.2021.101190","volume":"50","author":"B Cicu\u00e9ndez","year":"2021","unstructured":"Cicu\u00e9ndez, B., Ruiz-Garrido, I., Mora, A. & Sabio, G. Stress kinases in the development of liver steatosis and hepatocellular carcinoma. Mol. Metab. 50, 101190 (2021).","journal-title":"Mol. Metab."},{"key":"27885_CR62","doi-asserted-by":"publisher","DOI":"10.1017\/S0029665118002756","author":"NM Delzenne","year":"2019","unstructured":"Delzenne, N. M. et al. Contribution of the gut microbiota to the regulation of host metabolism and energy balance: a focus on the gut-liver axis. Proc. Nutr. Soc. https:\/\/doi.org\/10.1017\/S0029665118002756 (2019).","journal-title":"Proc. Nutr. Soc."},{"key":"27885_CR63","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/nrg2918","volume":"12","author":"AL Barab\u00e1si","year":"2011","unstructured":"Barab\u00e1si, A. L., Gulbahce, N. & Loscalzo, J. Network medicine: A network-based approach to human disease. Nat. Rev. Genet. 12, 56\u201368 (2011).","journal-title":"Nat. Rev. Genet."},{"key":"27885_CR64","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/9521073","author":"Y Ding","year":"2020","unstructured":"Ding, Y. et al. Integrating pharmacology and microbial network analysis with experimental validation to reveal the mechanism of composite sophora colon-soluble capsule against ulcerative colitis. Evid.-Based Complement. Altern. Med. https:\/\/doi.org\/10.1155\/2020\/9521073 (2020).","journal-title":"Evid.-Based Complement. Altern. Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-27885-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-27885-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-27885-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T09:10:21Z","timestamp":1673601021000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-27885-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,13]]},"references-count":64,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["27885"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-27885-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-1784103\/v2","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-1784103\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,13]]},"assertion":[{"value":"5 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"724"}}